Champions Oncology (CSBR) Operating Income (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Operating Income of -$276000.0 in Q1 2026, down 249.19% quarter-over-quarter from $185000.0 in Q4 2025, and down 106.13% on a YoY basis from $4.5 million in Q1 2025.
Champions Oncology (CSBR) Operating Income (2010 - 2026) Analysis & Trends
Champions Oncology's Operating Income history runs 17 years deep, the most recent figure standing at -$276000.0 for Q1 2026.
- In Q1 2026, Operating Income fell 106.13% year-over-year to -$276000.0; the TTM figure through Jan 2026 stood at -$2.6 million (down 141.74% YoY), while the FY2025 annual figure was $4.6 million, up 161.9% from the prior year.
- Operating Income was -$276000.0 for Q1 2026 at Champions Oncology, down from $185000.0 in the prior quarter.
- In the past five years, Operating Income ranged from a high of $4.5 million in Q1 2025 to a low of -$2.6 million in Q1 2024.
- Historically, Operating Income has averaged -$479823.5 across 5 years, with a median of -$284000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Operating Income tumbled 28028.57% in 2023, then soared 274.58% in 2025.
- A 5-year view of Operating Income shows it stood at $7000.0 in 2022, then sank by 28028.57% to -$2.0 million in 2023, then jumped by 137.44% to $732000.0 in 2024, then tumbled by 74.73% to $185000.0 in 2025, then tumbled by 249.19% to -$276000.0 in 2026.
- The last three Operating Income figures came in at -$276000.0 (Q1 2026), $185000.0 (Q4 2025), and -$527000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -276,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -276,000.00 |
| Oct 31, 2025 | 185,000.00 |
| Jul 31, 2025 | -527,000.00 |
| Apr 30, 2025 | -2.01 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 732,000.00 |
| Jul 31, 2024 | 1.33 Mn |
| Apr 30, 2024 | -271,000.00 |
| Jan 31, 2024 | -2.58 Mn |
| Oct 31, 2023 | -1.96 Mn |
| Jul 31, 2023 | -2.55 Mn |
| Apr 30, 2023 | -2.52 Mn |
| Jan 31, 2023 | -2.46 Mn |
| Oct 31, 2022 | 7,000.00 |
| Jul 31, 2022 | -284,000.00 |
| Apr 30, 2022 | -311,000.00 |
| Jan 31, 2022 | 830,000.00 |
| Oct 31, 2021 | 263,000.00 |
| Jul 31, 2021 | -175,000.00 |
| Apr 30, 2021 | -648,000.00 |